Communiqués PMV Pharmaceuticals, Inc.

Actions

PMVP

US69353Y1038

Marché Fermé - Nasdaq Autres places de cotation 22:00:00 16/07/2024			Varia. 5j.	Varia. 1 janv.
1,68 ^USD	+3,07 %		+14,29 %	-45,81 %

29/05	PMV Pharmaceuticals et Foundation Medicine vont developper un diagnostic compagnon pour le Rezatapopt	MT
29/05	Foundation Medicine et PMV Pharma annoncent leur collaboration pour le developpement d'un diagnostic compagnon pour le Rezatapopt	CI

Communiqués

Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !

Inscription 100% Gratuite

PMV Pharmaceuticals to Participate at Upcoming Investor Conferences in June	30/05	AQ
Foundation Medicine and PMV Pharma Announce Collaboration to Develop Companion Diagnostic for Rezatapopt, a First-In-Class, Investigational, Selective p53 Y220C Reactivator	29/05	BU
Foundation Medicine and PMV Pharma Announce Collaboration to Develop Companion Diagnostic for Rezatapopt, a First-In-Class, Investigational, Selective p53 Y220C Reactivator	29/05	AQ
PMV Pharmaceuticals Reports First Quarter 2024 Financial Results and Corporate Highlights	09/05	AQ
PMV Pharmaceuticals Announces First Patient Dosed in Global Tumor-Agnostic Phase 2 PYNNACLE Trial for Rezatapopt in TP53 Y220C-Positive Solid Tumors	27/03	AQ
PMV Pharmaceuticals PYNNACLE Phase I Data of Rezatapopt in Advanced Ovarian Cancer Featured in Late-Breaking Oral Presentation at 2024 SGO Annual Meeting on Women’s Cancer	18/03	AQ
PMV Pharmaceuticals Reports Full Year 2023 Financial Results and Corporate Highlights	29/02	AQ
PMV Pharmaceuticals to Participate in the TD Cowen 44th Annual Health Care Conference	26/02	AQ
PMV Pharmaceuticals Announces Prioritization of PC14586 Clinical Development and Extended Cash Runway	18/01	AQ
PMV Pharmaceuticals Strengthens Leadership with Key Appointments as Company Advances into Late-Stage Development	05/01	AQ
PMV Pharmaceuticals Reports Third Quarter 2023 Financial Results and Corporate Highlights	09/11	AQ
PMV Pharmaceuticals Updated PC14586 Phase 1 Data Demonstrated Anti-Tumor Activity Across Multiple Solid Tumor Types With a TP53 Y220C Mutation	12/10/23	AQ
PMV Pharmaceuticals to Present Updated Phase 1 Data on PC14586 at the 2023 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics and Host a KOL Webinar	11/10/23	AQ
PMV Pharmaceuticals to Present Updated Phase 1 Data on PC14586 at the 2023 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics	20/09/23	AQ
PMV Pharmaceuticals Reports Second Quarter 2023 Financial Results and Corporate Highlights	09/08/23	AQ
PMV Pharmaceuticals to Participate in the Goldman Sachs Global Healthcare Conference	06/06/23	AQ
PMV PHARMACEUTICALS, INC. : Results of Operations and Financial Condition, Financial Statements and Exhibits (form 8-K)	10/05/23	AQ
PMV Pharmaceuticals Reports First Quarter 2023 Financial Results and Corporate Highlights	10/05/23	AQ
PMV PHARMACEUTICALS, INC. : Amendments to Articles of Inc. or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits (form 8-K)	28/04/23	AQ
PMV PHARMACEUTICALS, INC. Management's Discussion and Analysis of Financial Condition and Results of Operations. (form 10-K)	01/03/23	AQ

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Communiqués PMV Pharmaceuticals, Inc.

Actions

PMVP

US69353Y1038

Communiqués

Filtres